Clinquest Group and TNO sign licensing agreement on protein for inflammatory disorders

Clinquest obtains exclusive worldwide rights to clinical development and commercialization

08-Mar-2007

Clinquest Group and TNO have signed a license and collaboration agreement that provides Clinquest with the exclusive rights to worldwide clinical development and commercialization of CQ-07001, a candidate for anti-inflammatory and tissue regeneration applications. Under the terms of the agreement, TNO will receive milestone fees and royalty payments, but financial details were not disclosed.

CQ-07001 is an endogenous human protein that has shown to be a powerful agonist to Toll-Like Receptor 3 (TLR 3). The 10 human Toll-Like Receptors (TLR) are generally implicated in recognizing pathogens and inducing immune responses and as such, TLRs play in important role in maintaining the body's capacity to counter harmful invaders. Studies performed by TNO have shown that TLR 3, in contrast to the other TLRs, is stimulated by CQ-07001 and subsequently triggers anti-inflammatory and tissue repair responses. This capacity of CQ-07001 makes it a promising candidate for clinical development aimed at various anti-inflammatory and tissue regeneration applications - both fields offer large market potential.

Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance